{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Islam S"],"funding":["NCI NIH HHS","National Institutes of Health","NIH HHS"],"pagination":["1406"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8310324"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(7)"],"pubmed_abstract":["Human T-cell leukemia virus type 1 (HTLV-1) is a retrovirus that infects at least 10 million people worldwide and is associated with the development of T-cell lymphoma (TCL). The treatment of TCL remains challenging and new treatment options are urgently needed. With the goal of developing a novel therapeutic approach for TCL, we investigated the activity of the clinical formulation of oncolytic reovirus (Reolysin, Pelareorep) in TCL models. Our studies revealed that HTLV-1-negative TCL cells were highly sensitive to Reolysin-induced cell death, but HTLV-1-positive TCL cells were resistant. Consistent with these data, reovirus displayed significant viral accumulation in HTLV-1-negative cells, but failed to efficiently replicate in HTLV-1-positive cells. Transcriptome analyses of HTLV-1-pos"],"journal":["Viruses"],"pubmed_title":["Targeting JAK/STAT Signaling Antagonizes Resistance to Oncolytic Reovirus Therapy Driven by Prior Infection with HTLV-1 in Models of T-Cell Lymphoma."],"pmcid":["PMC8310324"],"funding_grant_id":["R41 CA271967","P30CA023074","R01CA172443","R01CA190789","R01 CA190789"],"pubmed_authors":["Islam S","Espitia CM","Carew JS","Nawrocki ST","Persky DO"],"additional_accession":[]},"is_claimable":false,"name":"Targeting JAK/STAT Signaling Antagonizes Resistance to Oncolytic Reovirus Therapy Driven by Prior Infection with HTLV-1 in Models of T-Cell Lymphoma.","description":"Human T-cell leukemia virus type 1 (HTLV-1) is a retrovirus that infects at least 10 million people worldwide and is associated with the development of T-cell lymphoma (TCL). The treatment of TCL remains challenging and new treatment options are urgently needed. With the goal of developing a novel therapeutic approach for TCL, we investigated the activity of the clinical formulation of oncolytic reovirus (Reolysin, Pelareorep) in TCL models. Our studies revealed that HTLV-1-negative TCL cells were highly sensitive to Reolysin-induced cell death, but HTLV-1-positive TCL cells were resistant. Consistent with these data, reovirus displayed significant viral accumulation in HTLV-1-negative cells, but failed to efficiently replicate in HTLV-1-positive cells. Transcriptome analyses of HTLV-1-pos","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Jul","modification":"2025-04-19T02:48:39.825Z","creation":"2022-02-11T06:24:53.776Z"},"accession":"S-EPMC8310324","cross_references":{"pubmed":["34372612"],"doi":["10.3390/v13071406"]}}